Diabetic retinopathy: An update on treatment.

Diabetic retinopathy is a progressive disease that results from vascular injury due to chronic hyperglycemia. It is the leading cause of blindness in working-age adults in the US and is usually asymptomatic until late stages. Treatment with laser photocoagulation is effective at preventing severe vision loss; thus, diabetic patients should be referred for regular screening by an ophthalmologist. New inhibitors of vascular endothelial growth factor may provide targeted nonsurgical treatment to improve vision in diabetic retinopathy.

[1]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[2]  Judy E. Kim,et al.  Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. , 2009, Archives of ophthalmology.

[3]  R. Klein,et al.  Diabetic retinopathy in a multi-ethnic cohort in the United States. , 2006, American journal of ophthalmology.

[4]  Stephen J. Aldington,et al.  Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. , 2004, Archives of ophthalmology.

[5]  G. Lutty,et al.  Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. , 2002, American journal of ophthalmology.

[6]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[7]  R. Larson,et al.  Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. , 2009, Ophthalmology.

[8]  M. Farah,et al.  Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  N. Bressler,et al.  Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. , 2006, Ophthalmology.

[10]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[11]  Ronald Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. , 2008, Ophthalmology.

[12]  T. Wong,et al.  Management of diabetic retinopathy: a systematic review. , 2007, JAMA.